Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

ABSTRACT:

Purpose

Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies optimally targeting the tumors of individual patients.

Experimental design

We first developed a panel of new physiologic models for study of PDAC, expanding surgical PDAC tumor samples in culture using short-term culture and conditional reprogramming with the Rho kinase inhibitor Y-27632, and creating matched patient-derived xenografts (PDX). These were evaluated for sensitivity to a large panel of clinical agents, and promising leads further evaluated mechanistically.

Results

Only a small minority of tested agents was cytotoxic in minimally passaged PDAC cultures in vitro Drugs interferi

SUBMITTER: Beglyarova N 

PROVIDER: S-EPMC5161635 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature